# Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $255,946

## Abstract

Project Summary
 Type I Interferons (IFN-Is) are cytokines with potent anti-viral and proinflammatory activities. As such they
are tightly regulated to provide enough antiviral effects while not causing over and health disrupting inflammation.
Disorders where IFN-Is dysregulation is known to cause pathology are termed type I Interferonopathies.
 Down syndrome (DS) is the most common genetic cause of intellectual and developmental disabilities in
children and young adults with Incidence in US of about 1 in 600 individuals. Individuals with DS often have
cardiac and gastrointestinal abnormalities. Additionally, they have a number of immune-related problems from
increased susceptibility to an array of infectious diseases to autoimmunity. Unfortunately, the exact molecular
mechanism leading to these immune defects has not been elucidated.
 COVID-19 is a disease caused by a coronavirus, Severe Acute Respiratory Syndrome (SARS) -CoV-2.
Infections by SARS-CoV-2 are now present in every country around the globe, causing unprecedented public
health burden. SARS-CoV is known to interfere with IFN-I induction and signaling. To which extent SARS-CoV-
2 can cause illness in individuals with DS is currently unknown. DS is, in most cases, caused by an extra
chromosome 21, on which the receptors for type I Interferons (IFNAR1 and IFNAR2) are encoded. How this
gene dosage effects are contributing to SARS-CoV-2 pathophysiology is not understood. This proposal is built
around the hypothesis that relative amounts of IFNAR1 and IFNAR2 are the essential factors controlling SARS-
CoV-2 pathophysiology. To address this hypothesis, we propose to study DS patients in vitro at the molecular
level to determine the functional significance of dose of these genes in regulating IFN pathway in humans during
SARS-CoV-2 infection.
 Deeper understanding of molecular regulation of IFN-I in DS in the context of SARS-CoV-2 will allow us to
better understand how to approach clinical management of disease.

## Key facts

- **NIH application ID:** 10158984
- **Project number:** 3R01AI150300-01S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Dusan Bogunovic
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $255,946
- **Award type:** 3
- **Project period:** 2020-09-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10158984

## Citation

> US National Institutes of Health, RePORTER application 10158984, Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome (3R01AI150300-01S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10158984. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*